Neuroplasticity and stimulation of the Vagus Nerve: Integrative review of advances in the treatment of epilepsy.
PDF (Português (Brasil))

Keywords

refractory epilepsy, Vagus Nerve Stimulation, pharmacological therapy, side effects, multidisciplinary treatment, technological innovation.

How to Cite

Fernandes do Vale, G., De Queiroz Cunha, L., Cardoso Felipe , M. C., De Azevedo Assunção, L. F., Rosado Cantídio , M. O., Marinho Filho, F., Rocha Bezerra, K. S., Leandro Bezerra, M. B., Jovino de Oliveira, E., & Fernandes de Holanda, A. L. (2023). Neuroplasticity and stimulation of the Vagus Nerve: Integrative review of advances in the treatment of epilepsy. Brazilian Journal of Implantology and Health Sciences, 5(5), 2355–2374. https://doi.org/10.36557/2674-8169.2023v5n5p2355-2374

Abstract

Introduction: Refractory epilepsy represents a challenge in neurology, affecting the quality of life of patients who do not respond to conventional pharmacological therapies. Vagus Nerve Stimulation (VNS) emerges as a promising approach. Methodology: This integrative review was based on 29 studies on VNS in the treatment of refractory epilepsy. The PICO strategy was used to construct the research question and articles were selected from databases such as MEDLINE/PubMed, Science Direct and LILACS. Results: VNS proved to be effective in reducing the frequency of epileptic seizures, with around 8% of patients achieving freedom from seizures. Side effects, such as headache and skin irritation, were mild and well tolerated. The therapy was especially beneficial for patients with specific epilepsy syndromes. However, the high cost of VNS can be a barrier for many patients. Conclusion: VNS is a safe and effective approach for the treatment of refractory epilepsy. Early intervention may be particularly beneficial, especially in pediatric patients. Future technological innovations could make ENV more accessible and effective.

https://doi.org/10.36557/2674-8169.2023v5n5p2355-2374
PDF (Português (Brasil))

References

Beghi E, et al. Global, regional, and national burden of epilepsy, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(4):357–375.

Howland RH. Vagus nerve stimulation. Curr Behav Neurosci Rep. 2014;1(2):64–73.

Pan American Health Organization. Mais da metade das pessoas com epilepsia na América Latina e no Caribe não recebem tratamento [Internet]. 2019 [cited 2023 Oct 6]. Available from: https://www.paho.org/pt/noticias/24-1-2019-mais-da-metade-das-pessoas-com-epilepsia-na-america-latina-e-no-caribe-nao.

Löscher W, et al. Drug resistance in epilepsy: Clinical impact, potential mechanisms, and new innovative treatment options. Pharmacol Rev. 2020;72(3):606–638.

Morris GL, et al. Evidence-based guideline update: Vagus nerve stimulation for the treatment of epilepsy: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81(16):1453–1459.

Abassi Z, et al. Factors Affecting Vagus Nerve Stimulation Outcomes in Epilepsy. Front Neurol. 2019;10:916.

Fang S, et al. Neuroimmunomodulation of vagus nerve stimulation and the therapeutic implications. J Neuroimmunol. 2023;367:577585.

Fan L, et al. Research progress of vagus nerve stimulation in the treatment of epilepsy. Front Neurosci. 2019;13:819.

González R, et al. Vagus nerve stimulation for the treatment of epilepsy. Seizure. 2019;68:52-60.

Kavčič A. Early Intervention with Vagus Nerve Stimulation in Pediatric Patients with Drug-Resistant Epilepsy: A Single-Center Experience. Neuromodulation. 2019;22(1):85-90.

Lampros IL, et al. The long-term outcome of vagus nerve stimulation in patients with refractory epilepsy. Epilepsy Behav. 2021;114:107313.

Marras CE, et al. Cost-effectiveness of Vagus Nerve Stimulation (VNS) in the Treatment of Patients with Drug-Resistant Epilepsy. Front Neurol. 2020;11:160.

He X, et al. Cirurgia ressectiva para epilepsia pós-traumática resistente a medicamentos: preditores de resultado de convulsão. J Neurocirurgia. 2019;133:1568–1575.

Brown MG, et al. Concurrent brain-responsive and vagus nerve stimulation for treatment of drug-resistant focal epilepsy. Epilepsy Behav. 2022;129:108653.

Nair DR, et al. Nine-year prospective efficacy and safety of brain-responsive neurostimulation for focal epilepsy. Neurology. 2020;95(9):e1244-e1256.

Martorell-Llobregat C, et al. The role of vagus nerve stimulation in the treatment of refractory epilepsy: clinical outcomes and impact on quality of life. Neurologia (Engl Ed). 2022;37(6):450-458.

Thompson SL, et al. A Review of Parameter Settings for Invasive and Non-Invasive Vagus Nerve Stimulation (VNS) Applied in Neurological and Psychiatric Disorders. Front Neurosci. 2021;15. doi: 10.3389/fnins.2021.709436.

Fan J-J, et al. Research Progress of Vagus Nerve Stimulation in the Treatment of Epilepsy. CNS Neuroscience & Therapeutics. 2019;25(11):1222–1228. doi: 10.1111/cns.13209.

Abbasi M, et al. Factors Affecting Vagus Nerve Stimulation Outcomes in Epilepsy. Neurology Research International. 2021;2021:1-12. doi: 10.1155/2021/9927311.

Fang Y-T, et al. Neuroimmunomodulation of Vagus Nerve Stimulation and the Therapeutic Implications. Front Aging Neurosci. 2023;15:1173987.

Marras CE, et al. Health Technology Assessment Report on Vagus Nerve Stimulation in Drug-Resistant Epilepsy. Int J Environ Res Public Health. 2020;17(17):6150.

Lampros M, et al. Transcutaneous Vagus Nerve Stimulation (T-VNS) and Epilepsy: A Systematic Review of the Literature. Seizure. 2021;91:40-48.

National Guideline Centre (UK). Evidence Review: Vagus Nerve Stimulation: Epilepsies in Children, Young People and Adults: Diagnosis and Management: Evidence Review 14. London: National Institute for Health and Care Excellence (NICE); 2022.

Bakhtiarzadeh F, et al. Neurostimulation as a Putative Method for the Treatment of Drug-Resistant Epilepsy in Patient and Animal Models of Epilepsy. Basic Clin Neurosci. 2023;14(1):1-18.

Kavčič A. Efficacy and Tolerability of Vagus Nerve Stimulation Therapy (VNS) in Slovenian Epilepsy Patients: Younger Age and Shorter Duration of Epilepsy Might Result in Better Outcome. Acta Clin Croatica. 2019.

Wredem R, et al. Transcutaneous Auricular Vagus Nerve Stimulation Induces Stabilizing Modifications in Large-Scale Functional Brain Networks: Towards Understanding the Effects of TaVNS in Subjects with Epilepsy. Sci Rep. 2021;11(1).

Wan L, et al. Clinical characteristics and treatment outcomes of pediatric patients with postencephalitic epilepsy characterized by epileptic spasms. Seizure. 2021;84:116-121.

Guery D, Rheims S. Clinical Management of Drug Resistant Epilepsy: A Review on Current Strategies. Neuropsychiatr Dis Treat. 2021;17:2229-2242.

von Wrede R, Surges R. Transcutaneous vagus nerve stimulation in the treatment of drug-resistant epilepsy. Auton Neurosci. 2021;235:102840.

Li ST, et al. Therapeutic effects of children with refractory epilepsy after vagus nerve stimulation in Taiwan. Pediatrics Neonatol. 2020;61(6):606-612.

Spindler P, Vajkoczy P, Schneider UC. Closed-loop vagus nerve stimulation. Patient-tailored therapy or undirected treatment? Interdiscip Neurosurg. 2021;23:101003.

Muthiah N, et al. Comparison of traditional and closed loop vagus nerve stimulation for treatment of pediatric drug-resistant epilepsy: A propensity-matched retrospective cohort study. Seizure. 2022;94:74-81.

Youn SE, et al. Long-term results of vagus nerve stimulation in children with Dravet syndrome: Time-dependent, delayed antiepileptic effect. Epilepsy Res. 2021;174:106665.

Brodtkorb E, et al. Epilepsy patients with and without perceived benefit from vagus nerve stimulation: A long-term observational single center study. Seizure. 2019;72:28-32.

Hödl S, et al. Pre-ictal heart rate variability alterations in focal onset seizures and response to vagus nerve stimulation. Seizure. 2021;86:175-180.

Martorell-Llobregat C, et al. The role of vagus nerve stimulation in the treatment of refractory epilepsy: Clinical outcomes and impact on quality of life. Papel de la estimulación del nervio vago en el tratamiento de la epilepsia refractaria. Resultados clínicos e impacto en la calidad de vida. Neurologia. 2019.

Kobayashi Y, et al. Clinical manifestations and epilepsy treatment in Japanese patients with pathogenic CDKL5 variants. Brain Dev. 2021;43(4):505-514.

Abdelmoity SA, et al. The efficacy and tolerability of auto-stimulation-VNS in children with Lennox-Gastaut syndrome. Seizure. 2021;86:168-174.

Oliveira TVHF, et al. Reducing VNS stimulation parameters: Is it safe? É seguro reduzir parâmetros de estimulação do VNS? Arq Bras Neurocir. 2022;41(1):e19–e25.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright (c) 2023 Gustavo Fernandes do Vale, Leticia De Queiroz Cunha, Maria Clara Cardoso Felipe , Luiz Felipe De Azevedo Assunção, Maria Oitava Rosado Cantídio , Fernando Marinho Filho, Keren Suely Rocha Bezerra, Maria Beatriz Leandro Bezerra, Edson Jovino de Oliveira, Ana Larissa Fernandes de Holanda